FDA Approves Gilead’s ‘Game Changing’ Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag

All NewsJune 20, 2025

Gilead’s FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent